EGFR and neoplasm: In addition, saracatinib offers the advantage of simultaneous EGFR/Src inhibition, possibly providing a further benefit in terms of tumor growth control and preventing the onset of Src-mediated resistance to EGFR inhibitors, as previously reported [37–39].